|
|
333 Lakeside Drive
Foster City, CA 94404 USA
phone:(650) 574-3000
fax:(650) 578-9264
|
|
| Symbol |
GILD |
| Exchange |
NASDAQ |
| Founded |
1987 |
| Employees |
|
|
|
| www.gilead.com
|
|
|
|
 |
| Summary Description |
| Medicines for life-threatening diseases |
|
| Management |
| John C. Martin, PhD, Chairman and Chief Executive Officer; John F. Milligan, PhD, President and Chief Operating Officer; Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer; Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs; Kevin Young, Executive Vice President, Commercial Operations |
| |
|
|
|
|
|
|
|
| Keywords |
| fibrosis, idiopathic, hiv/aids, steatohepatitis, nonalcoholic |
|
|
|
| Description |
|
Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. Headquartered in Foster City, California, the company has expanded rapidly over the past two decades, with annual revenues now exceeding $5 billion, operations spanning four continents and a staff of approximately 4, 000 employees. Gilead�s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members